© 2019 F. Hoffmann-La Roche Ltd - NP/OTHE/1901/0002
This Roche COVID-19 site is intended to serve as a non-promotional resource to facilitate transparent scientific exchange, based on the questions asked by healthcare professionals, regarding developments in scientific research relating to COVID-19 and Roche medicines. It is intended only for healthcare professionals. The content on this website may include scientific information about experimental or investigational compounds, and indications that are not approved or valid in your country. Registration status and prescribing information of Roche medicines may differ between countries. Roche does not support, endorse or recommend the unapproved use of any Roche medicine in your country, including those discussed on this website.
Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice and Roche accepts no responsibility for access to or use of any content.
By clicking “I confirm” below you are confirming that you are a healthcare professional and that you have read and understood this notice and that you are requesting access to the information.
Return to HOME
COVID-19 and Tocilizumab Further Information for Health Care Professionals
Document contains: Update on current investigation of Tocilizumab in COVID-19 patients, covering the following topics: COVID-19 overview | Tocilizumab in patients with COVID-19 pneumonia | COVACTA trial | Key takeaways
Download PDF: COVID-19_Tocilizumabexternal_5.pdf